Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by S Gala
TCS on gifting funds to NRI Son
S M Gala (Head: F & A) (93 Points) 13 February 2024 A mother wish to remit a sum of Rs 50 lakhs to her NRI Son to help him buying home in place of his country of residence. Queries 1. Can she do this transaction by remittance into his sons NRE/NRO Account? 2. If yes, is Tcs applicable on such remittance and at what are? 3. How do the said TCS be claimed by the NRI Son?
Walnut Creek Library Foundation
Michael Barrington is the author of three books including Becoming Anya (2021). He is currently completing a spy novel The Ethiopian Affair. He has also written numerous short stories, articles and book reviews and is a regular contributor to ‘Alive’ Magazine/ East Bay. Michael lives in Concord with his wife Annie Jacquemet. Vincent Chu is the author of the debut story collection Like a Champion. His fiction has appeared in Muumuu House, STILL Magazine, East Bay Review, and elsewhere.
Walnut Creek Library Foundation
Meet the Authors Join us for an evening with 20 notable Bay Area authors including Donia Bijan, Jason Fagone, Christine Hyung-Oak Lee, Laleh Khadivi, Joyce Maynard, Emily Murphy and Kevin Smokler.
Assessment and Characterization of Gaps in Literature of Resource Utilization and Economic Burden in Inflammatory Myopathies
Inflammatory myopathies (IM) including polymyositis (PM), dermatomyositis (DM), and inclusion-body myositis (IBM) pose a significant burden on patients and payers. These rare diseases have no approved treatments or clinical guidelines, however their cost burden equals or exceeds that of rheumatoid arthritis and systemic sclerosis. There are significant knowledge gaps on resource utilization and cost burden in IM.
Indirect Treatment Comparison Of Newer Treatments In Relapsed / Refractory Multiple Myeloma
Relapsed / refractory multiple myeloma (rrMM) remains challenging to treat effectively. Results of two major phase III randomized controlled trials (RCTs), ASPIRE for carfilzomib and ELOQUENT-2 for elotuzumab, both in combination with lenalidomide and dexamethasone (CLD and ELD respectively) in rrMM were compared to placebo plus lenalidomide and dexamethasone (LD). We performed an indirect treatment comparison (ITC) to compare CLD versus ELD.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with S
Contact S, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack